Precigen (PGEN) AI Stock Analysis

• Market Cap: $1.05B
• Dividend Yield: N/A
• Average Volume (3M): 14.91M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: -1.12%
• EPS Growth: 20.77%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 297,972,930
• 10 Day Avg. Volume: 7,133,325
• 30 Day Avg. Volume: 14,908,791
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: 91.53
• Enterprise Value/Gross Profit: -1.14K
• Enterprise Value/Ebitda: -3.26
• 1Y Price Target: $8.25
• Price Target Upside: 135.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 61 Neutral
• Price Target: $3.00 ▼(-14.53% Downside)

Precigen's overall stock score reflects a mix of strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The company's recent strategic moves and product approvals provide growth potential, but financial instability remains a significant risk.

Positive Factors

FDA Approval

The FDA approval for PAPZIMEOS as a therapy for RRP enhances Precigen's market position, offering a new treatment option and potential revenue growth.

Strategic Partnership

The partnership with Catalent ensures a reliable supply chain for PAPZIMEOS, potentially improving operational efficiency and market reach.

Financial Strengthening

The $125M loan strengthens Precigen's financial position, supporting commercialization efforts and potential market expansion.

Negative Factors

Negative Profit Margins

Consistently negative profit margins indicate ongoing operational inefficiencies, challenging Precigen's ability to achieve sustainable profitability.

Negative Equity

Negative equity suggests potential solvency issues, limiting financial flexibility and increasing risk for investors and stakeholders.

Poor Cash Generation

Negative operating cash flow reflects poor cash generation, which can strain Precigen's ability to fund operations and growth initiatives.

Precigen Business Overview & Revenue Model

Company Description

Precigen (PGEN) is a biotechnology company focused on harnessing the power of gene and cell therapies to develop transformative treatments for cancer and other genetic disorders. Operating within the life sciences sector, Precigen utilizes its proprietary technology platforms, including UltraCar-T and Precigen's gene delivery systems, to create innovative therapeutic solutions. The company's core products include engineered T-cell therapies and other advanced biologics designed to improve patient outcomes in oncology and other areas of unmet medical need.

How the Company Makes Money

Precigen generates revenue through a combination of product sales, partnerships, and collaborations with pharmaceutical companies. The company derives income from licensing its proprietary technology platforms to other firms, as well as from milestone payments and royalties associated with the development and commercialization of its therapies. Significant partnerships, particularly those with major pharmaceutical players, enhance its revenue potential by providing access to broader markets and resources for research and development. Additionally, Precigen may receive funding through government grants and contracts aimed at advancing innovative therapies.

Precigen Financial Statement Overview

Summary

Precigen's financial performance is severely weak, with declining revenues, negative profit margins, and financial instability. The income statement shows significant operational losses, the balance sheet reflects negative equity and high liabilities, and cash flow analysis indicates reliance on external financing.

Income Statement

Precigen's income statement reflects significant challenges with declining revenues and negative profit margins. The gross profit margin is negative at -2.17% TTM, indicating costs exceed sales. The net profit margin is also severely negative at -3728.79% TTM, showing substantial losses. Revenue has decreased drastically over recent periods, with a TTM revenue growth rate of -32.56%. EBIT and EBITDA margins are also negative, highlighting ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows financial instability, with negative stockholders' equity of -$14.06 million TTM, indicating liabilities exceed assets. The debt-to-equity ratio isn't applicable due to negative equity, but the presence of high total liabilities of $142.85 million suggests significant leverage. The equity ratio is negative, further emphasizing the weak financial position. Return on equity is not applicable due to negative equity.

Cash Flow

Cash flow analysis shows continuous negative free cash flow, with a slight improvement in operating cash flow. Free cash flow growth rate is slightly positive at 1.95% TTM, but remains negative overall at -$75.26 million. The operating cash flow to net income ratio is 0.45 TTM, reflecting some operational cash generation despite losses. However, the company is heavily reliant on financing activities for cash inflow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.34M	3.92M	6.22M	26.91M	14.27M	103.18M
Gross Profit	-348.00K	-342.00K	-4.74M	20.57M	45.49M	47.66M
EBITDA	-121.97M	-123.50M	-89.23M	-66.00M	-84.07M	-70.41M
Net Income	-124.50M	-126.23M	-95.90M	28.32M	-92.17M	-170.52M
Balance Sheet
Total Assets	101.90M	145.27M	151.04M	215.98M	359.86M	314.59M
Cash, Cash Equivalents and Short-Term Investments	59.75M	97.91M	62.85M	55.95M	108.66M	100.12M
Total Debt	5.15M	5.50M	7.10M	51.42M	190.07M	182.28M
Total Liabilities	107.79M	106.75M	32.55M	89.72M	252.51M	247.41M
Stockholders Equity	-36.78M	66.73M	118.50M	126.26M	107.35M	67.17M
Cash Flow
Free Cash Flow	-68.19M	-76.76M	-68.47M	-69.97M	-63.02M	-84.55M
Operating Cash Flow	-66.28M	-68.17M	-66.93M	-65.05M	-55.77M	-77.02M
Investing Cash Flow	-59.71M	-20.71M	-3.09M	226.42M	-74.54M	27.78M
Financing Cash Flow	108.09M	110.58M	29.59M	-155.29M	121.19M	32.70M

Precigen Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGEN, the sentiment is Neutral. The current price of 3.51 is below the 20-day moving average (MA) of 4.02, above the 50-day MA of 3.05, and above the 200-day MA of 1.84, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 46.38 is Neutral, neither overbought nor oversold. The STOCH value of 25.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PGEN.

Precigen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGEN	61 Neutral	$1.05B	―	-668.03%	―	-1.12%	20.77%
RLAY	55 Neutral	891.37M	-2.65	-43.42%	―	-76.27%	22.77%
MGTX	41 Neutral	658.06M	-4.01	-5321.11%	―	366.84%	-35.87%
TYRA	41 Neutral	691.26M	-7.26	―	―	―	-5.63%
MNMD	40 Neutral	811.86M	-7.29	―	―	―	39.66%
SANA	33 Underperform	864.06M	-3.14	―	―	―	7.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Precigen Corporate Events

Precigen Secures $125M Loan for PAPZIMEOS Expansion

On September 3, 2025, Precigen, Inc. announced a loan agreement with Pharmakon Advisors, LP, securing a 5-year senior secured term loan facility of up to $125 million. This non-dilutive financing, with an initial $100 million funded at closing, aims to support the commercialization of PAPZIMEOS, a novel immunotherapy, in the US and potentially expand into international markets. The agreement strengthens Precigen’s financial position, enabling it to pursue pediatric and other HPV-related indications, and is expected to drive significant growth, positioning the company as a leading biopharma innovator.

Precigen Enters Commercial Supply Agreement with Catalent

On August 13, 2025, Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, Inc. This agreement mandates Catalent to provide various services including analytical, development, processing, validation, and product maintenance for Precigen’s product, PAPIZEMOS. The agreement establishes Catalent as the exclusive provider for Precigen’s commercial fill and finish manufacturing needs for PAPIZEMOS, with terms including annual price adjustments and a minimum purchase requirement. The initial term of the agreement is three years, with automatic one-year renewals unless terminated by either party. This collaboration is expected to streamline Precigen’s manufacturing processes and potentially enhance its market positioning by ensuring consistent product supply.

Precigen’s PAPZIMEOS Receives FDA Approval for RRP

On August 18, 2025, Precigen, Inc. announced that its product PAPZIMEOS received FDA approval as the first and only therapy for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. This approval positions PAPZIMEOS as a potential standard-of-care treatment, offering a new paradigm for managing RRP, which was previously treated mainly through surgical interventions. The approval is expected to significantly impact Precigen’s market positioning and provide a new therapeutic option for the estimated 27,000 adult RRP patients in the US.

Precigen Announces Key Approvals at Annual Meeting

At the Annual Meeting of Stockholders on June 26, 2025, Precigen, Inc. announced several key approvals, including an amendment to increase the shares available under its 2023 Omnibus Incentive Plan by 11.5 million. Additionally, stockholders approved increasing the company’s authorized shares of common stock by 300 million and ratified Deloitte & Touche LLP as the independent accounting firm for 2025. These decisions are expected to impact Precigen’s operational flexibility and shareholder value positively.